Congress authorized the FDA to determine whether a drug is “in shortage in the United States.” The FDA’s determination of a drug shortage ...

Eli Lilly s Pleasant Prairie facility expansion gets final approval, paving the way for a 3 billion Kenosha County investment ...

Compounding pharmacies have been allowed to essentially make a cheaper version of Eli Lilly's Zepbound, but they have to stop ...

Hims & Hers (HIMS) went all-in on weight-loss drugs. It bet big on cheaper, compounded versions of blockbuster GLP-1 treatments like ...

Adults with insulin-treated type 2 diabetes had greater HbA1c reductions and larger improvement in time in range with use of ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now ...

Eli Lilly's stock dipped slightly by -0.27% to close at $822.51, outperforming the S&P 500’s larger 1.07% drop. Despite a ...

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

Mounjaro, a tirzepatide drug prescribed for diabetes, could help people without this condition lose 13% of their body weight ...

We have compared the Deep Research agents available in ChatGPT and Gemini in detail to find out which one excels at research ...

Large-scale compounding facilities have to stop making tirzepatide, the main ingredient in blockbuster obesity drug Zepbound, Wednesday.